134 related articles for article (PubMed ID: 38704890)
1. The combination of methionine adenosyltransferase 2A inhibitor and methyltransferase like 3 inhibitor promotes apoptosis of non-small cell lung cancer cells and produces synergistic anti-tumor activity.
Xuan YF; Lu S; Ou YJ; Bao XB; Huan XJ; Song SS; Miao ZH; Wang YQ
Biochem Biophys Res Commun; 2024 Jul; 716():150011. PubMed ID: 38704890
[TBL] [Abstract][Full Text] [Related]
2. Combined inhibition of MTAP and MAT2a mimics synthetic lethality in tumor models via PRMT5 inhibition.
Bedard GT; Gilaj N; Peregrina K; Brew I; Tosti E; Shaffer K; Tyler PC; Edelmann W; Augenlicht LH; Schramm VL
J Biol Chem; 2024 Jan; 300(1):105492. PubMed ID: 38000655
[TBL] [Abstract][Full Text] [Related]
3. Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis.
Frau M; Feo F; Pascale RM
J Hepatol; 2013 Oct; 59(4):830-41. PubMed ID: 23665184
[TBL] [Abstract][Full Text] [Related]
4. MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage.
Kalev P; Hyer ML; Gross S; Konteatis Z; Chen CC; Fletcher M; Lein M; Aguado-Fraile E; Frank V; Barnett A; Mandley E; Goldford J; Chen Y; Sellers K; Hayes S; Lizotte K; Quang P; Tuncay Y; Clasquin M; Peters R; Weier J; Simone E; Murtie J; Liu W; Nagaraja R; Dang L; Sui Z; Biller SA; Travins J; Marks KM; Marjon K
Cancer Cell; 2021 Feb; 39(2):209-224.e11. PubMed ID: 33450196
[TBL] [Abstract][Full Text] [Related]
5. Targeting the methionine-methionine adenosyl transferase 2A- S -adenosyl methionine axis for cancer therapy.
Guo J; Yang Y; Buettner R; Rosen ST
Curr Opin Oncol; 2022 Sep; 34(5):546-551. PubMed ID: 35788128
[TBL] [Abstract][Full Text] [Related]
6. The mechanism of m
Liu S; Li Q; Li G; Zhang Q; Zhuo L; Han X; Zhang M; Chen X; Pan T; Yan L; Jin T; Wang J; Lv Q; Sui X; Xie T
Cell Death Dis; 2020 Nov; 11(11):969. PubMed ID: 33177491
[TBL] [Abstract][Full Text] [Related]
7. Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous
Konteatis Z; Travins J; Gross S; Marjon K; Barnett A; Mandley E; Nicolay B; Nagaraja R; Chen Y; Sun Y; Liu Z; Yu J; Ye Z; Jiang F; Wei W; Fang C; Gao Y; Kalev P; Hyer ML; DeLaBarre B; Jin L; Padyana AK; Dang L; Murtie J; Biller SA; Sui Z; Marks KM
J Med Chem; 2021 Apr; 64(8):4430-4449. PubMed ID: 33829783
[TBL] [Abstract][Full Text] [Related]
8. S-adenosylmethionine biosynthesis is a targetable metabolic vulnerability of cancer stem cells.
Strekalova E; Malin D; Weisenhorn EMM; Russell JD; Hoelper D; Jain A; Coon JJ; Lewis PW; Cryns VL
Breast Cancer Res Treat; 2019 May; 175(1):39-50. PubMed ID: 30712196
[TBL] [Abstract][Full Text] [Related]
9. Overview of Methionine Adenosyltransferase 2A (MAT2A) as an Anticancer Target: Structure, Function, and Inhibitors.
Li C; Gui G; Zhang L; Qin A; Zhou C; Zha X
J Med Chem; 2022 Jul; 65(14):9531-9547. PubMed ID: 35796517
[TBL] [Abstract][Full Text] [Related]
10. Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo.
Meng J; Dai B; Fang B; Bekele BN; Bornmann WG; Sun D; Peng Z; Herbst RS; Papadimitrakopoulou V; Minna JD; Peyton M; Roth JA
PLoS One; 2010 Nov; 5(11):e14124. PubMed ID: 21124782
[TBL] [Abstract][Full Text] [Related]
11. m
Jin D; Guo J; Wu Y; Du J; Yang L; Wang X; Di W; Hu B; An J; Kong L; Pan L; Su G
J Hematol Oncol; 2019 Dec; 12(1):135. PubMed ID: 31818312
[TBL] [Abstract][Full Text] [Related]
12. Structure-Based Design and Optimization of Methionine Adenosyltransferase 2A (MAT2A) Inhibitors with High Selectivity, Brain Penetration, and In Vivo Efficacy.
Faridoon ; Zheng J; Zhang T; Tong S; Liu T; Cui J; Xu H; Hu D; Shen Y; Yin Y; Zhao D; Tan C; Dong X; Chen J; Ji F; Tong C; Li JJ; Li J; Zhang G
J Med Chem; 2024 Jun; 67(11):9431-9446. PubMed ID: 38818879
[TBL] [Abstract][Full Text] [Related]
13. mTORC1-independent translation control in mammalian cells by methionine adenosyltransferase 2A and S-adenosylmethionine.
Alam M; Shima H; Matsuo Y; Long NC; Matsumoto M; Ishii Y; Sato N; Sugiyama T; Nobuta R; Hashimoto S; Liu L; Kaneko MK; Kato Y; Inada T; Igarashi K
J Biol Chem; 2022 Jul; 298(7):102084. PubMed ID: 35636512
[TBL] [Abstract][Full Text] [Related]
14. Targeting S-adenosylmethionine biosynthesis with a novel allosteric inhibitor of Mat2A.
Quinlan CL; Kaiser SE; Bolaños B; Nowlin D; Grantner R; Karlicek-Bryant S; Feng JL; Jenkinson S; Freeman-Cook K; Dann SG; Wang X; Wells PA; Fantin VR; Stewart AE; Grant SK
Nat Chem Biol; 2017 Jul; 13(7):785-792. PubMed ID: 28553945
[TBL] [Abstract][Full Text] [Related]
15. S-Adenosylmethionine Synthesis Is Regulated by Selective N
Shima H; Matsumoto M; Ishigami Y; Ebina M; Muto A; Sato Y; Kumagai S; Ochiai K; Suzuki T; Igarashi K
Cell Rep; 2017 Dec; 21(12):3354-3363. PubMed ID: 29262316
[TBL] [Abstract][Full Text] [Related]
16. Fragment-Based Design of a Potent MAT2a Inhibitor and
De Fusco C; Schimpl M; Börjesson U; Cheung T; Collie I; Evans L; Narasimhan P; Stubbs C; Vazquez-Chantada M; Wagner DJ; Grondine M; Sanders MG; Tentarelli S; Underwood E; Argyrou A; Smith JM; Lynch JT; Chiarparin E; Robb G; Bagal SK; Scott JS
J Med Chem; 2021 May; 64(10):6814-6826. PubMed ID: 33900758
[TBL] [Abstract][Full Text] [Related]
17. A patent review of MAT2a inhibitors (2018-2021).
Atkinson SJ; Evans L; Scott JS
Expert Opin Ther Pat; 2022 Oct; 32(10):1043-1053. PubMed ID: 36043503
[TBL] [Abstract][Full Text] [Related]
18. 8-Cl-Ado and 8-NH
Guo J; Buettner R; Du L; Li Z; Liu W; Su R; Chen Z; Che Y; Zhang Y; Ma R; Nguyen LXT; Moore RE; Khyatiben P; Chen MH; Patrick P; Wu X; Marcucci G; Wang L; Horne D; Chen J; Yang Y; Rosen ST
Leukemia; 2024 Jun; 38(6):1236-1245. PubMed ID: 38643304
[TBL] [Abstract][Full Text] [Related]
19. The U6 snRNA m
Pendleton KE; Chen B; Liu K; Hunter OV; Xie Y; Tu BP; Conrad NK
Cell; 2017 May; 169(5):824-835.e14. PubMed ID: 28525753
[TBL] [Abstract][Full Text] [Related]
20. Expression of methionine adenosyltransferase 2A in renal cell carcinomas and potential mechanism for kidney carcinogenesis.
Wang X; Guo X; Yu W; Li C; Gui Y; Cai Z
BMC Cancer; 2014 Mar; 14():196. PubMed ID: 24636201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]